Nab -paclitaxel: Novel clinical and experimental evidence in pancreatic cancer

Zeitschrift fur Gastroenterologie

Volumn 52, Issue 4, 2014, Pages 360-366

  Neesse, A ^a   Michl, P ^a   Tuveson, D A ^b   Ellenrieder, V ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Cold Spring Harbor Laboratory Cold Spring Harbor ^*  (United States)

Author keywords

chemoresistance; drug delivery; nab paclitaxel; pancreatic cancer

Indexed keywords

CREMOPHOR; DOCETAXEL; ERLOTINIB; GEMCITABINE; HUMAN ALBUMIN; OSTEONECTIN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE ARREST; DEPLETION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG UPTAKE; HUMAN; KARNOFSKY PERFORMANCE STATUS; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); STROMA; TUMOR MICROENVIRONMENT; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PREVALENCE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PANCREATIC NEOPLASMS; PREVALENCE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84898540333     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0034-1366002     Document Type: Article

References (55)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin: 2013; 63 11 30
2. Porta M., Fabregat X., Malats N. et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol: 2005; 7 189 197
3. Watanabe I., Sasaki S., Konishi M. et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas: 2004; 28 160 165 (Pubitemid 38269776)
4. Khorana A. A., Fine R. L. Pancreatic cancer and thromboembolic disease. Lancet Oncol: 2004; 5 655 663 (Pubitemid 40267849)
5. Seufferlein T., Porzner M., Becker T. et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol: 2013; 51 1395 1440
6. Seufferlein T., Bachet J. B., Van Cutsem E. et al. ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: 2012; 23 07 vii33 vii40
7. Burris H. A. 3rd, Moore M. J., Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol: 1997; 15 2403 2413 (Pubitemid 27251144)
8. Moore M. J., Goldstein D., Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol: 2007; 25 1960 1966 (Pubitemid 46972777)
9. Wacker B., Nagrani T., Weinberg J. et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res: 2007; 13 3913 3921 (Pubitemid 47037599)
10. Van Cutsem E., Vervenne W. L., Bennouna J. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol: 2009; 27 2231 2237
11. Conroy T., Desseigne F., Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med: 2011; 364 1817 1825
12. Von Hoff D. D., Ervin T., Arena F. P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med: 2013; 369 1691 1703
13. Wani M. C., Taylor H. L., Wall M. E. et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc: 1971; 93 2325 2327
14. Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature: 1979; 277 665 667 (Pubitemid 9114288)
15. McGuire W. P., Hoskins W. J., Brady M. F. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med: 1996; 334 1 6 (Pubitemid 26012496)
16. Nabholtz J. M., Gelmon K., Bontenbal M. et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol: 1996; 14 1858 1867 (Pubitemid 26185461)
17. Bonomi P., Kim K., Fairclough D. et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol: 2000; 18 623 631 (Pubitemid 30078543)
18. Oettle H., Arnold D., Esser M. et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs: 2000; 11 635 638
19. Shukuya T., Yasui H., Boku N. et al. Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol: 2010; 40 1135 1138
20. Maeda S., Motoi F., Onogawa T. et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol: 2011; 16 539 545
21. Gebbia N., Gebbia V. Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma. Eur J Cancer: 1996; 32A 1822 1823 (Pubitemid 26306901)
22. Whitehead R. P., Jacobson J., Brown T. D. et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol: 1997; 15 2414 2419 (Pubitemid 27251145)
23. Lam A. P., Sparano J. A., Vinciguerra V. et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol: 2010; 33 121 124
24. Kim Y. J., Bang S., Park J. Y. et al. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol: 2009; 63 529 533
25. Gradishar W. J. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol: 2005; 3 348 349 (Pubitemid 41387353)
26. Kumar G. N., Walle U. K., Bhalla K. N. et al. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol: 1993; 80 337 344 (Pubitemid 23187695)
27. Brouwer E., Verweij J., De Bruijn P. et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos: 2000; 28 1141 1145
28. Ibrahim N. K., Desai N., Legha S. et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res: 2002; 8 1038 1044 (Pubitemid 34517637)
29. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release: 2008; 132 171 183
30. Yardley D. A. nab-Paclitaxel mechanisms of action and delivery. J Control Release: 2013; 170 365 372
31. Gradishar W. J., Tjulandin S., Davidson N. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol: 2005; 23 7794 7803 (Pubitemid 46657376)
32. Socinski M. A., Langer C. J., Okamoto I. et al. Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol: 2013; 24 314 321
33. Socinski M. A., Bondarenko I., Karaseva N. A. et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol: 2012; 30 2055 2062
34. Von Hoff D. D., Ramanathan R. K., Borad M. J. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol: 2011; 29 4548 4554
35. Hosein P. J., de Lima Lopes G. Jr, Pastorini V. H. et al. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol: 2013; 36 151 156
36. Ko A. H., Truong T. G., Kantoff E. et al. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol: 2012; 70 875 881
37. Alvarez R., Musteanu M., Garcia-Garcia E. et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer: 2013; 109 926 933
38. Sparreboom A., Scripture C. D., Trieu V. et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res: 2005; 11 4136 4143 (Pubitemid 40791578)
39. Gardner E. R., Dahut W. L., Scripture C. D. et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res: 2008; 14 4200 4205
40. John T. A., Vogel S. M., Tiruppathi C. et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol: 2003; 284 L187 L196 (Pubitemid 35471272)
41. Desai N., Trieu V., Yao Z. et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res: 2006; 12 1317 1324 (Pubitemid 43342524)
42. Maeda H., Wu J., Sawa T. et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release: 2000; 65 271 284 (Pubitemid 30122932)
43. Prabhakar U., Maeda H., Jain R. K. et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res: 2013; 73 2412 2417
44. Neesse A., Frese K. K., Chan D. S. et al. SPARC independent drug delivery and anti-tumor effects of nab-paclitaxel in genetically engineered mice. Gut: 2013; Sep 25 10.1136/gutjnl-2013-305559 [Epub ahead of print].
45. Frese K. K., Neesse A., Cook N. et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov: 2012; 2 260 269
46. Neesse A., Michl P., Frese K. K. et al. Stromal biology and therapy in pancreatic cancer. Gut: 2011; 60 861 868
47. Thompson C. B., Shepard H. M., O'Connor P. M. et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther: 2010; 9 3052 3064
48. Olive K. P., Jacobetz M. A., Davidson C. J. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science: 2009; 324 1457 1461
49. Jacobetz M. A., Chan D. S., Neesse A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut: 2013; 62 112 120
50. Provenzano P. P., Cuevas C., Chang A. E. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell: 2012; 21 418 429
51. Sato N., Fukushima N., Maehara N. et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene: 2003; 22 5021 5030 (Pubitemid 37026400)
52. Mantoni T. S., Schendel R. R., Rodel F. et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther: 2008; 7 1806 1815
53. Infante J. R., Matsubayashi H., Sato N. et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol: 2007; 25 319 325 (Pubitemid 350003021)
54. Shao H., Tang H., Salavaggione O. E. et al. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol: 2011; 6 998 1005
55. Weerapana E., Wang C., Simon G. M. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature: 2010; 468 790 795